Next Article in Journal
Gene Environment Interactions and Predictors of Colorectal Cancer in Family-Based, Multi-Ethnic Groups
Next Article in Special Issue
Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics
Previous Article in Journal / Special Issue
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessFeature PaperReview
J. Pers. Med. 2018, 8(1), 9; https://doi.org/10.3390/jpm8010009

P450 Pharmacogenetics in Indigenous North American Populations

1
Departments of Pharmaceutics, University of Washington, Seattle, WA 98195, USA
2
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA
3
Southcentral Foundation, Anchorage, AK 99508, USA
4
United States Public Health Service, Department of Human Services, Washington, DC 20201, USA
5
Center for Alaska Native Health Research, University of Alaska Fairbanks, Fairbanks, AK 99775, USA
6
Bioethics & Humanities, University of Washington, Seattle, WA 98195, USA
*
Author to whom correspondence should be addressed.
Received: 18 December 2017 / Revised: 19 January 2018 / Accepted: 22 January 2018 / Published: 1 February 2018
(This article belongs to the Special Issue Cytochrome P450 Variation in Pharmacogenomics)
Full-Text   |   PDF [6143 KB, uploaded 1 February 2018]   |  

Abstract

Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy. View Full-Text
Keywords: American Indian; Alaska Native; First Nations; Inuit; Mexican Amerindians; cytochrome P450; pharmacogenetics; allele frequency; drug metabolism American Indian; Alaska Native; First Nations; Inuit; Mexican Amerindians; cytochrome P450; pharmacogenetics; allele frequency; drug metabolism
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Henderson, L.M.; Claw, K.G.; Woodahl, E.L.; Robinson, R.F.; Boyer, B.B.; Burke, W.; Thummel, K.E. P450 Pharmacogenetics in Indigenous North American Populations. J. Pers. Med. 2018, 8, 9.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top